News | Radiopharmaceuticals and Tracers | September 18, 2015

Molecular Imaging Study Reveals Improved Detection of Early Recurrent Prostate Cancer

Research with new PET/CT imaging agent changes management in nearly half of cases

molecular imaging, imaging agent, GA-68 PSMA, improved detection, early recurrent, prostate cancer

September 18, 2015 — A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. In the study, the imaging agent — Ga-68 prostate-specific membrane antigen (Ga-68 PSMA) — used with positron emission tomography and computed tomography (PET/CT), changed management in 44 percent more cases than another widely used agent.

"This is the first prospective comparative trial evaluating detection rates and management impact of the more widely available radiopharmaceutical F-18 fluoromethylcholine (FMC) and the recently developed Ga-68 PSMA PET tracer agent in men with prostate cancer," said Joshua James Morigi, M.D., lead author of the study. "We specifically addressed men with prostate cancer and low PSA levels, at which current imaging techniques struggle in detecting disease."

The researchers, of St. Vincent's Hospital, Sydney, Australia, evaluated 39 prostate cancer patients who had rising PSA following first-round treatment and were eligible for further targeted therapy. Patients on systemic treatment were excluded. Ga-68 PSMA PET/CT, F-18 FMC PET/CT and diagnostic CT were undertaken in all patients sequentially between January and April 2015 and assessed by masked, experienced nuclear medicine physicians. Researchers then documented scan results and management impact changes, together with histological follow-up, if feasible. Of the patients enrolled, 89 percent had only their prostate gland removed, while the other 11 percent were post-radiation treatment.

"Our main finding is that even at extremely low PSA levels (<0.5), PSMA was able to detect sites of possible recurrence in 50 percent of patients while FMC detected possible recurrence in only 12.5 percent," Morigi states. "As a result of these high detection rates, PSMA also demonstrated a very high management impact in our patient cohort (63 percent), having an added value over FMC in 44 percent," he continued. "These findings have important ramifications for the management of men with early biochemical failure and suggest that imaging-guided therapy even in low PSA range may be possible."

Histological follow-up was available for nine patients (24 percent), and nine out of nine PSMA-positive lesions were consistent with prostate cancer. The one lesion positive on FMC and negative on PSMA resulted at biopsy as a false positive. Researchers concluded that in patients with biochemical failure and low PSA, PSMA demonstrated a significantly higher detection rate with a high overall impact on management. This suggests that Ga-68 PSMA PET/CT will be an effective imaging tool for early detection of prostate cancer recurrence.

For more information: www.jnm.snmjournals.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...